Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder,  director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, shares his advice for the management of early relapse in patients with multiple myeloma.

According to Usmani, one approach to this situation is not appropriate for all patients. Physicians should consider each regimen that could potentially be used for first relapse to decide which option is best for an individual patient. If there are 2 regimens with similar benefit, convenience for the patient should also be considered.

2019 International Congress on Hematologic Malignancies

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Multiple Myeloma

BMS-22-OSD1240 - /clinical/multiple-myeloma

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

PER® Congress on Hematologic Malignancies (Winter Hematology®)

Saad Z. Usmani, MD, FACP, shares his advice for the management of early relapse in patients with multiple myeloma.

Dr. Usmani Discusses Management of Early Relapse in Myeloma